Molecular pharmaceuticsOct 22, 2026

A Modified GLP-1R Activator Improves Blood Sugar Control in Tumor-Bearing Rats Without Worsening Appetite Loss or Weight Loss

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 23, 2026

Abstract

Cbi-Ex4 improved glucose tolerance without inducing anorexia, weight loss, or malaise in rodent models.

Cancer anorexia-cachexia syndrome is associated with insulin resistance and impaired glucose tolerance.
Limited treatment options exist that improve metabolic regulation without worsening anorexia in cancer patients.
A new compound, Cbi-Ex4, was developed to target GLP-1 receptors without crossing the blood-brain barrier.
Cbi-Ex4 demonstrated effectiveness in enhancing glucose control while avoiding the adverse effects seen with native Ex4.
These results suggest that targeting peripheral GLP-1 receptors could be a viable strategy for managing metabolic dysfunction in cancer.

Simplified

Cancer anorexia-cachexia syndrome (CACS) is a prevalent and debilitating complication of malignancy, characterized by reduced food intake, loss of skeletal muscle mass, and severe metabolic dysfunction. Insulin resistance and impaired glucose tolerance are prominent features of CACS and contribute to worsened prognosis, yet treatment options that improve metabolic regulation without exacerbating anorexia are limited. Although GLP-1 receptor (GLP-1R) agonists effectively enhance glucose control, their centrally mediated anorectic and aversive effects limit their use in cancer patients. To address this limitation, we developed a peripherally restricted GLP-1R agonist by conjugating exendin-4 (Ex4) to dicyanocobinamide (Cbi), a vitamin B12-derived corrin ring with minimal blood-brain barrier penetration. Here, we evaluate Cbi-Ex4 in vitro and across healthy and tumor-bearing rodent models. Cbi-Ex4 retained GLP-1R agonism and improved glucose tolerance without inducing anorexia, weight loss, or malaise, in contrast to native Ex4. These findings support peripheralized GLP-1R agonism as a promising strategy to improve metabolic dysfunction in cancer without worsening malaise and cachexia.

Full Text

Full text is available at the source.

View Full Text ↗

A Modified GLP-1R Activator Improves Blood Sugar Control in Tumor-Bearing Rats Without Worsening Appetite Loss or Weight Loss

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief